enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...

3. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

4. Empagliflozin/linagliptin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin/linagliptin

   The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).

5. Heart failure is reversed with new gene therapy in animal ...

   www.aol.com/news/heart-failure-reversed-gene...

   Heart failure has historically been irreversible, but a new study suggests that could change. At the University of Utah, scientists used a new gene therapy that reversed heart failure in animals.

6. Widely-used heart drug linked to increased dementia risk - AOL

   www.aol.com/article/2016/05/06/heart-drug...

   For premium support please call: 800-290-4726 more ways to reach us

7. Empagliflozin/linagliptin/metformin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin/linagliptin/...

   To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.